These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19509234)

  • 1. Therapeutic potential of "rexinoids" in cancer prevention and treatment.
    Tanaka T; De Luca LM
    Cancer Res; 2009 Jun; 69(12):4945-7. PubMed ID: 19509234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RXR: from partnership to leadership in metabolic regulations.
    Desvergne B
    Vitam Horm; 2007; 75():1-32. PubMed ID: 17368310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoids as chemopreventive agents.
    Ralhan R; Kaur J
    J Biol Regul Homeost Agents; 2003; 17(1):66-91. PubMed ID: 12757022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.
    Liby KT; Yore MM; Sporn MB
    Nat Rev Cancer; 2007 May; 7(5):357-69. PubMed ID: 17446857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic modulation of retinoid X receptors - SAR and therapeutic potential of RXR ligands and recent patents.
    Schierle S; Merk D
    Expert Opin Ther Pat; 2019 Aug; 29(8):605-621. PubMed ID: 31298602
    [No Abstract]   [Full Text] [Related]  

  • 6. RAR and RXR modulation in cancer and metabolic disease.
    Altucci L; Leibowitz MD; Ogilvie KM; de Lera AR; Gronemeyer H
    Nat Rev Drug Discov; 2007 Oct; 6(10):793-810. PubMed ID: 17906642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoid X receptors: X-ploring their (patho)physiological functions.
    Szanto A; Narkar V; Shen Q; Uray IP; Davies PJ; Nagy L
    Cell Death Differ; 2004 Dec; 11 Suppl 2():S126-43. PubMed ID: 15608692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO.
    Shankaranarayanan P; Rossin A; Khanwalkar H; Alvarez S; Alvarez R; Jacobson A; Nebbioso A; de Lera AR; Altucci L; Gronemeyer H
    Cancer Cell; 2009 Sep; 16(3):220-31. PubMed ID: 19732722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of selective nuclear receptor modulators: RAR and RXR as a case study.
    de Lera AR; Bourguet W; Altucci L; Gronemeyer H
    Nat Rev Drug Discov; 2007 Oct; 6(10):811-20. PubMed ID: 17906643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand Design for Modulation of RXR Functions.
    Martínez C; Souto JA; de Lera AR
    Methods Mol Biol; 2019; 2019():51-72. PubMed ID: 31359388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents.
    Garattini E; Gianni' M; Terao M
    Vitam Horm; 2007; 75():301-54. PubMed ID: 17368321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in drug design with RXR modulators.
    Vaz B; de Lera ÁR
    Expert Opin Drug Discov; 2012 Nov; 7(11):1003-16. PubMed ID: 22954251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of methyl farnesoate and related compounds with a crustacean retinoid X receptor.
    Wang YH; LeBlanc GA
    Mol Cell Endocrinol; 2009 Oct; 309(1-2):109-16. PubMed ID: 19486925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers.
    Pérez Santín E; Germain P; Quillard F; Khanwalkar H; Rodríguez-Barrios F; Gronemeyer H; de Lera AR; Bourguet W
    J Med Chem; 2009 May; 52(10):3150-8. PubMed ID: 19408900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural and Structure-based RXR Ligand Scaffolds and Their Functions.
    Dominguez M; Alvarez S; de Lera AR
    Curr Top Med Chem; 2017; 17(6):631-662. PubMed ID: 27320335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ab initio fragment molecular orbital study of molecular interactions in liganded retinoid X receptor: specification of residues associated with ligand inducible information transmission.
    Ito M; Fukuzawa K; Ishikawa T; Mochizuki Y; Nakano T; Tanaka S
    J Phys Chem B; 2008 Sep; 112(38):12081-94. PubMed ID: 18729504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRalpha-preferential agonist possessing a sulfonamide moiety.
    Takamatsu K; Takano A; Yakushiji N; Morishita K; Matsuura N; Makishima M; Ali HI; Akaho E; Tai A; Sasaki K; Kakuta H
    ChemMedChem; 2008 Mar; 3(3):454-60. PubMed ID: 18157857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
    Desphande A; Xia G; Boerma LJ; Vines KK; Atigadda VR; Lobo-Ruppert S; Grubbs CJ; Moeinpour FL; Smith CD; Christov K; Brouillette WJ; Muccio DD
    Bioorg Med Chem; 2014 Jan; 22(1):178-85. PubMed ID: 24359708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
    Lippman SM; Heymach JV
    Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers.
    Atigadda VR; Kashyap MP; Yang Z; Chattopadhyay D; Melo N; Sinha R; Belyaeva OV; Chou CF; Chang PL; Kedishvili NY; Grubbs CJ; Renfrow MB; Muccio DD; Elmets CA; Athar M
    J Med Chem; 2022 Nov; 65(21):14409-14423. PubMed ID: 36318154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.